Sanctuary Advisors’s Syndax Pharmaceuticals SNDX Stock Holding History

Sanctuary Advisors’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-13,779	Closed	-$169K	–	2443
2025 Q1	$169K	Sell	13,779 -11,399	-45%	-$161K	﹤0.01%	2067
2024 Q4	$358K	Sell	25,178 -5,750	-19%	-$98.4K	﹤0.01%	1892
2024 Q3	$498K	Buy	+30,928	New	+$639K	﹤0.01%	1700

Other funds holding SNDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Sanctuary Advisors's SNDX Position: Q2 2025 in Review

Sanctuary Advisors sold out of Syndax Pharmaceuticals (SNDX) in Q2 2025, closing a stake of 13,779 shares — an estimated $169K sold.

Sanctuary Advisors first reported a position in SNDX in Q3 2024 and held it in 3 quarters. The position peaked at $498K in Q3 2024. 216 funds tracked by Wall St. Rank hold SNDX as of Q2 2025.

Sanctuary Advisors reported no remaining Syndax Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Sanctuary Advisors sold 13,779 Syndax Pharmaceuticals shares in Q2 2025, an estimated $169K.
Sanctuary Advisors first reported a position in Syndax Pharmaceuticals in Q3 2024 and held it in 3 quarters.
Sanctuary Advisors's Syndax Pharmaceuticals position peaked at $498K in Q3 2024.
216 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2025.

Based on Sanctuary Advisors's 13F filing for Q2 2025, filed 6 Jan 2026.